Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GC | P02774 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060109 | 1.00 | VDR (0.52) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6059789 | 1.00 | VDR (0.52) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6059788 | 1.00 | VDR (0.52) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6060114 | 0.97 | VDR (0.53) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6059807 | 0.97 | VDR (0.53) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6059607 | 0.92 | VDR (0.52) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6060805 | 0.92 | VDR (0.52) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL7715728 | 0.88 | VDR (0.58) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL7716794 | 0.88 | VDR (0.58) | VDRNR1I2PGRADORA3SLC6A2 | |
| SCHEMBL6060632 | 0.87 | VDR (0.48) | VDRNR1I2PGRADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071344-B1 | Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments | SCHERING AG (DE) | 2006-07-04 | — | — | US | disclosed |
| US-20050227951-A1 | Verification of translation | STEINMEYER ANDREAS | 2005-10-13 | — | — | US | disclosed |
| EP-1025082-B1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | STEINMEYER ANDREAS (DE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227951-A1 | Verification of translation | CYP2R1, CYP24A1, VDR | VDR 3/4885NR1I2 1968/4885PGR 1344/4885 |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | CYP2R1, CYP24A1, VDR | VDR 3/4885NR1I2 414/4885PGR 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.